Table 2 Incidence Rates and Risks of AVF/AVG Dysfunction in ADPKD and Non-ADPKD Groups.

From: Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease

Time Period

ADPKD Group

Non-ADPKD Group (Reference)

Crude

Competing Risk

No. of Events

Person- Years

Incidence Rate*

No. of Events

Person- Years

Incidence Rate*

HR (95% CI)

P

SHR (95% CI)

P

All periods

371

1460

25.40

1023

4820

21.22

1.13 (1.01–1.28)

0.038

1.14 (1.01–1.28)

0.031

Within 90 days

51

131

38.83

191

390

48.99

0.79 (0.58–1.08)

0.138

0.79 (0.58–1.08)

0.137

Within 180 days

113

246

45.85

372

725

51.31

0.89 (0.72–1.10)

0.289

0.90 (0.73–1.10)

0.300

First year

197

443

44.42

543

1312

41.40

1.07 (0.91–1.26)

0.418

1.08 (0.92–1.27)

0.361

Within 5 years

335

1223

27.38

946

3832

24.69

1.08 (0.96–1.23)

0.213

1.09 (0.96–1.23)

0.168

1–10 years

174

1003

17.35

473

3428

13.80

1.23 (1.03–1.46)

0.022

1.19 (1.00–1.41)

0.045

  1. *Per 102 person-years.
  2. Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; ADPKD, autosomal dominant polycystic kidney disease; HR, hazard ratio; SHR, subdistribution hazard ratio; CI, confidence interval.